Cargando…
A targeted approach to reducing rates of discontinuation and dose reduction in patients receiving sorafenib or regorafenib
Background: Sorafenib and regorafenib are oral multikinase inhibitors used to treat some cancers, but adverse events for both drugs are common and often cause patients to discontinue therapy or reduce their dose within several months of initiating therapy. Pharmacists have the potential to prevent d...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764342/ http://dx.doi.org/10.1080/21556660.2019.1658310 |